ClinicalTrials.gg
TerminatedNCT04073615Updated May 2, 2024

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

A Phase 1 interventional study of Rivoceranib and Trifluridine/Tipiracil in Metastatic Colorectal Cancer, sponsored by Elevar Therapeutics. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by Elevar Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
Phase 2 portion of the study was not performed due to redirection of the rivoceranib development plan by the Sponsor.

From the registry’s dates

  • Primary completion was May 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing apatinib in Colorectal Neoplasms — none open to participants now, none under way, none of them phase 3. apatinib · Colorectal Neoplasms.

Enrollment
13th of 16
29 · median 41
Started
2019
with 2 others
Phase 1
Only one
of the 16
Registered
14th of 16
by date
Lead sponsor
1 of 16
Elevar Therapeutics

Among the 16 studies testing apatinib in Colorectal Neoplasms, this one is the 13th largest by enrollment, is one of 3 that started in 2019, is the only one in phase 1, and was the 14th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

None of the 16 studies testing apatinib in Colorectal Neoplasms is open now. The open studies under Colorectal Neoplasms, anywhere →

Where they have run

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing apatinib in Colorectal Neoplasms as a file.
02

Study summary

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.

Read the detailed description

This a multicenter open-label study comparing safety, tolerability and efficacy of rivoceranib and trifluridine/tipiracil monotherapies, and the combination of rivoceranib plus trifluridine/tipiracil in participants with mCRC. Participants with histologically or cytologically definitive adenocarcinoma of the colon or rectum who have progressed following standard of care therapy for colorectal cancer (CRC) will be randomly assigned (1:1:2) to rivoceranib, trifluridine/tipiracil or rivoceranib plus trifluridine/tipiracil treatment groups.

The study will consist of an initial phase 1b portion to assess the safety of and determine the RP2D of rivoceranib in combination with trifluridine/tipiracil. A subsequent phase 2 portion will assess the primary endpoint of progression free survival (PFS) by investigator assessment. When a participant discontinues rivoceranib and/or trifluridine/tipiracil for any reason, the participant will enter the 12-month survival follow-up period until withdrawal of consent from the study, lost to follow-up, end of the study or death, whichever occurs earlier.

The maximum duration of the study is estimated to be 36 months, which includes screening, treatment, and follow-up phases.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological or cytological confirmation of the diagnosis of mCRC
  2. Failure to respond or be intolerant of at least 2 prior regimens of standard anti-cancer treatments (study treatment must be or greater for mCRC). Failed prior treatments may include:

    • Fluoropyrimidines-based chemotherapy
    • Irinotecan-based chemotherapy
    • Oxaliplatin-based chemotherapy
    • Anti-Vascular Endothelial Growth Factor (VEGF) biological therapy
    • Anti-Epidermal Growth Factor Receptor (EGFR) therapy, if RAS wild-type
    • Immunotherapy (for example, nivolumab, pembrolizumab and ipilimumab), in participants with Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR). Participants who had received chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy would be considered as 1 prior line of therapy
  3. Have progressed based on imaging during or within 3 months of the last administration of most recent therapy
  4. Have , as defined by v1.1
  5. Adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days prior to Cycle 1 Day 1

    • (ANC) ≥1,500/mm3
    • ≥75,000/mm3
    • ≥9.0 g/dL
    • (according to Cockcroft-Gault Equation or by 24 hr urine collection) > 50 mL/min and serum creatinine \<1.0× (ULN)
    • (AST) and alanine transaminase (ALT) ≤3.0x ULN (≤5.0 × ULN for participants with liver involvement of their cancer)
    • ≤1.5 × ULN
    • Alkaline phosphatase ≤2.5 × ULN (≤5 × ULN with liver involvement of their cancer)
    • (INR) / partial thromboplastin time (PTT) ≤1.5 × ULN (Participants currently under treatment with anti-thrombotic agents such as warfarin or heparin with no abnormal coagulation values can participate in this study)
  6. Urinary protein \<2+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥ 2+, a 24-hour urine or urine protein/creatinine ratio must be collected and must demonstrate \<2 g of protein in 24 hours to allow participation in the study.
  7. Have an (ECOG) status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with rivoceranib or trifluridine/tipiracil
  2. Prior treatment with other VEGFR small molecule inhibitors (for example, regorafenib)
  3. Packed red blood cell transfusion or erythropoietin therapy within 14 days prior to first dose of study drug
  4. History of another within 3 years prior to Cycle 1 Day 1. A participant with the following malignancies is eligible for this study if, in the opinion of the Investigator, they do not pose a significant risk to :

    • Carcinoma of the skin without melanomatous features
    • Curatively treated cervical carcinoma in situ
    • Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (Tis)
    • Thyroid papillary cancer with prior treatment
    • Prostate cancer which has been surgically or medically treated and not likely to recur within 3 years
  1. Active renal dysfunction that requires dialysis treatments
  1. Active cardiac disease including any of the following:
  • Congestive heart failure (NYHA) ≥Class 2
  • Myocardial infarction less than 6 months before the start of Cycle 1 Day 1 of treatment

    1. Cardiac arrhythmias requiring antiarrhythmic therapy (beta-blockers or digoxin are permitted)
    1. History of uncontrolled hypertension (blood pressure ≥140/90 mmHg and/or change in antihypertensive medication within 7 days prior to first dose of study drug)
    1. History of antiangiogenic drug class-related severe adverse reactions, including uncontrolled hypertension or others related to prior therapy discontinuation and/or those that may indicate a higher risk to a participant' safety, in the Investigator's opinion, if provided further antiangiogenic treatment.
    1. History of vascular disease including arterial or venous embolic events (pulmonary embolism), other than hypertension, within 6 months prior to Cycle 1 Day 1 (for example, hypertensive crisis, hypertensive encephalopathy, stroke or [TIA], or significant peripheral vascular diseases) that, in the Investigator's opinion, may pose a risk to the participant on VEGF inhibitor therapy.
    1. History of thrombosis within 3 months prior to first dose of study drug that, in the Investigator's opinion, may place the participant at risk of side effects from antiangiogenics medications
    1. History of bleeding diathesis or clinically significant bleeding within 14 days prior to first dose of study drug
    1. Therapy with systemic anticoagulant or antithrombotic agents within 7 days prior to first dose of study drug that in the Investigator's opinion could interfere with clotting. The maximum allowable daily dose of aspirin is 325 milligram (mg).
    1. Participants with unstable seizure disorder requiring medication changes within 3 months of Cycle 1 Day 1 treatment
    1. Untreated or active central nervous system (CNS) or . Participants are eligible if have been treated and participants are neurologically returned to baseline or neurologically stable (expect for residual signs and symptoms related to the CNS treatment) for at least 4 weeks prior to first dose of study drug. In addition, participants must be either off , or on a stable dose or decreasing dose of ≤ 20 mg daily prednisone or prednisone-equivalent. A baseline radiological assessment of the brain will be performed on participants who have prior history of metastases with CNS involvement
    1. History of clinically significant glomerulonephritis, -proven nephritis, crystal nephropathy or other renal insufficiencies
    1. Unresolved adverse reactions >Grade 1 excluding peripheral neuropathy or treatment related myelosuppression
    1. Known to any of the study drugs, study drug classes, or any components of study drug formulations
    1. Inability to swallow oral medications
    1. An active malabsorption condition, or any other condition that in the opinion of the Investigator might affect the absorption of study drug
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Rivoceranib

    Participants will receive an oral dose of rivoceranib once per day on Days 1 through 28 of each 28-day cycle.

    Drug: Rivoceranib

  • Active comparator
    Trifluridine/tipiracil

    Participants will receive an oral dose of Trifluridine/tipiracil twice per day with food, on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.

    Drug: Trifluridine/Tipiracil

  • Experimental
    Rivoceranib and trifluridine/tipiracil

    Participants will receive a daily oral dose of rivoceranib on Days 1 through 28 and the recommended phase 2 dose (RP2D) of trifluridine/tipiracil twice per day between Days 1 to 5 and 8 to 12 of each 28-day cycle.

    Drug: Rivoceranib · Drug: Trifluridine/Tipiracil

Interventions

  • Film-coated tablets

    Also known as: Rivoceranib Mesylate, Apatinib Mesylate, Apatinib

  • DrugTrifluridine/Tipiracil

    Film-coated tablets

    Also known as: Lonsurf

06

What researchers measure

Primary outcomes

  1. (Phase 1b) Percentage of Participants with Dose-limiting Toxicity (DLT) During Cycle 1

    Time frame: Baseline up to 28 days

  2. (Phase 1b) Number of Participants with Adverse Events (AEs)investigator assessment

    Time frame: Baseline up to 3 years

  3. (Phase 1b) Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Baseline up to 3 years

  4. (Phase 2) Progression Free Survival (PFS) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Assessment

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. (Phase 1b and Phase 2) Overall Survival (OS)

    OS is the time from participant enrollment until death from any cause.

    Time frame: Up to approximately 3 years

  2. (Phase 2) Objective Response Rate (ORR)

    ORR per RECIST v1.1 by Investigator Assessment is defined as percentage of participants who will achieve confirmed Complete Response (CR) or Partial Response (PR).

    Time frame: Up to approximately 3 years

  3. Duration of Response (DoR)

    DoR per RECIST v1.1 by investigator assessment.

    Time frame: Up to approximately 3 years

  4. Time to Progression (TTP)

    TTP per RECIST v1.1 by investigator assessment.

    Time frame: Up to approximately 3 years

  5. (Phase 2) Disease Control Rate (DCR)

    DCR per RECIST v1.1 by investigator assessment.

    Time frame: Up to approximately 3 years

  6. (Phase 1b and 2) Number of Participants with Adverse Events (AEs) that Worsen in Severity as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Time frame: Up to approximately 3 years

07

Study locations

4 sites
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Vanderbilt University School of Medicine
    Nashville, Tennessee 37232, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in May 2023, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2019
First posted
Aug 29, 2019
StartActual
Nov 18, 2019
Primary completionActual
May 31, 2023
CompletionActual
May 31, 2023
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04073615
Lead sponsor
Elevar Therapeutics
Responsible party
Sponsor
First posted
Aug 29, 2019
Start date
Nov 18, 2019
Primary completion
May 31, 2023
Completion
May 31, 2023
Last update
May 2, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatinib

Start the discussion